Literature DB >> 12360462

A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.

D Patch1, C A Sabin, J Goulis, G Gerunda, L Greenslade, C Merkel, A K Burroughs.   

Abstract

BACKGROUND & AIMS: Patients who have had one variceal bleed are at high risk of rebleeding. Since its introduction, endoscopic variceal banding has been shown to be superior to needle sclerotherapy. Banding has not been compared with hepatic venous pressure-guided medical therapy (beta-blockers and nitrates).
METHODS: One hundred two patients with cirrhosis and a recent esophageal variceal bleed were randomized to either endoscopic banding (51 patients) or medical therapy (51 patients). The hepatic venous pressure gradient was measured in all patients at baseline, at 3 months (drug therapy arm), and at yearly intervals (all patients). Primary end points were death or rebleeding.
RESULTS: The 2 groups were well matched. Fifty-one percent were Pughs C, with a median Pughs score of 9.5. Nineteen patients rebled in the drug arm (median time, 24 days) and 27 patients in the banding arm (median time, 24 days). At 1 year, 43.7% of patients had bled in the drug arm compared with 53.8% in the banding arm (P = 0.25). Thirty-two percent of patients on medical therapy had died at 1 year, 22.5% on banding (P = 0.97).
CONCLUSIONS: In the prevention of variceal rebleeding, beta-blockers +/- nitrates are as effective as endoscopic banding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360462     DOI: 10.1053/gast.2002.35955

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

1.  Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.

Authors:  Shiv K Sarin; Manav Wadhawan; Rajesh Gupta; Hansa Shahi
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 2.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 3.  Portal hypertension--old problem, new therapeutic solutions.

Authors:  Markus Peck-Radosavljevic
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 4.  Evolution of endoscopic therapy for esophageal varices.

Authors:  G V Stiegmann
Journal:  Surg Endosc       Date:  2006-03-16       Impact factor: 4.584

5.  Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis.

Authors:  Lan Li; Chaohui Yu; Youming Li
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

Review 6.  Secondary prophylaxis in patients who have experienced portal hypertensive bleeding.

Authors:  Carlo Merkel; Sara Montagnese
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

7.  Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates.

Authors:  Sang Gyune Kim; Joseph J Larson; Ji Sung Lee; Terry M Therneau; W Ray Kim
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

Review 8.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 10.  Endoscopic treatments for portal hypertension.

Authors:  Gin-Ho Lo
Journal:  Hepatol Int       Date:  2017-11-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.